Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Rubidium Muriaticum
Generic Name
Rubidium Muriaticum
Active Ingredient
RubidiumCategory
Calcium [EPC]
Salt Form
Iodide
Variants
7
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 200 [hp_C]/1 | PELLET | ORAL | 37662-4028 |
| 500 [hp_C]/1 | PELLET | ORAL | 37662-4029 |
| 12 [hp_C]/1 | PELLET | ORAL | 37662-4025 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Rubidium Muriaticum, you must consult a qualified healthcare professional.
| 30 [hp_C]/1 | PELLET | ORAL | 37662-4026 |
| 100 [hp_C]/1 | PELLET | ORAL | 37662-4027 |
| 1 [hp_M]/1 | PELLET | ORAL | 37662-4030 |
| 6 [hp_C]/1 | PELLET | ORAL | 37662-4024 |
Detailed information about Rubidium Muriaticum
Rubidium is a chemical element and alkali metal used primarily as a diagnostic agent in positron emission tomography (PET) to evaluate myocardial perfusion. It belongs to the Calcium [EPC] and diagnostic radiopharmaceutical classes.
The dosage of Rubidium-82 for myocardial perfusion imaging is measured in units of radioactivity, specifically Megabecquerels (MBq) or millicuries (mCi). The standard adult dose typically ranges from 1,110 to 2,220 MBq (30 to 60 mCi) per injection.
In a standard PET MPI procedure, two doses are usually administered:
The total dose administered during a single imaging session should not exceed the maximum limits established by the facility's radiation safety officer, typically around 4,440 MBq (120 mCi) total.
Rubidium-82 is generally NOT approved for use in pediatric patients. The safety and effectiveness of Rubidium-82 in children have not been established. Because children are more sensitive to radiation exposure, alternative imaging modalities that do not involve ionizing radiation (such as echocardiography or MRI) are usually preferred unless the clinical benefit significantly outweighs the risks.
No specific dosage adjustments are required for patients with renal impairment because the physical decay of Rubidium-82 (75-second half-life) is much faster than renal excretion. However, the patient's hydration status should be monitored to ensure the eventual excretion of stable metabolites.
No dosage adjustments are necessary for patients with liver disease, as Rubidium is not metabolized by the liver.
Dosage in elderly patients is generally the same as in younger adults. However, healthcare providers must consider the patient's overall frailty and ability to remain still during the PET scan, as movement can blur the images and require repeat dosing.
Rubidium is administered exclusively by intravenous (IV) infusion by a qualified healthcare professional in a hospital or specialized imaging center.
Since Rubidium is administered by a healthcare professional during a scheduled medical procedure, a 'missed dose' in the traditional sense does not occur. If a procedure is interrupted, the healthcare provider will determine if a repeat dose is necessary based on the remaining radioactivity and the quality of the images obtained.
An overdose of Rubidium-82 would result in an unnecessary increase in radiation exposure. Because of the 75-second half-life, the radioactive dose decreases by half every minute.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Ensure you disclose all medications and supplements to your imaging team.
Most patients tolerate Rubidium-82 infusions very well. However, because it is often administered alongside pharmacological stress agents, side effects are common. Common reactions related to the procedure or the tracer include:
Rubidium-82 is a radioactive material and must be handled with extreme caution. It is only intended for use by healthcare professionals who are licensed and trained in the use of radiopharmaceuticals. Patients should be aware that while the radioactivity leaves the body quickly, they will be 'radioactive' for a very short period (approximately 10-15 minutes) following the injection.
As of 2024, the FDA-approved labeling for Rubidium-82 generators includes a warning regarding Unintended Radiation Exposure. This warning highlights the necessity of strictly following the manufacturer's instructions for generator elution (the process of extracting the Rubidium) and testing for Strontium breakthrough. Excessive Strontium levels can lead to long-term radiation-induced health complications, including an increased risk of certain cancers.
There are no drugs that are strictly 'contraindicated' due to a chemical reaction with Rubidium. However, certain drugs must be stopped because they interfere with the imaging results:
Rubidium-82 PET scans should NEVER be performed in the following circumstances:
Rubidium-82 is classified as FDA Pregnancy Category C (under the old system). There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. However, all radiopharmaceuticals have the potential to cause fetal harm. If a scan is absolutely necessary, the lowest possible dose should be used, and the patient should be informed of the potential risks of radiation-induced birth defects or childhood cancers. Use in fertility treatments is not relevant as Rubidium is a one-time diagnostic agent.
It is not known whether Rubidium-82 is excreted in human milk. However, because many drugs are excreted in milk and because of the potential for radiation exposure to the nursing infant, breastfeeding should be interrupted. Due to the very short half-life of Rubidium-82 (75 seconds), the radioactivity in the mother's body disappears almost entirely within an hour. Most guidelines recommend pumping and discarding milk for at least 1-4 hours after the procedure to be completely safe.
Safety and effectiveness in pediatric patients have not been established. The use of ionizing radiation in children is a major concern because their tissues are more sensitive and they have a longer life expectancy in which to develop radiation-induced cancers. If a Rubidium scan is considered, it must be performed at a specialized pediatric center with adjusted dosing protocols.
Rubidium-82 is a potassium analog. It is actively transported from the blood into the myocardial cells by the Na+/K+-ATPase pump. This pump maintains the electrochemical gradient across the cell membrane by moving three sodium ions out of the cell and two potassium (or rubidium) ions into the cell. The rate of uptake of Rubidium into the heart muscle is directly proportional to the myocardial blood flow. In areas where coronary arteries are narrowed, blood flow is reduced, resulting in less Rubidium being delivered and taken up by the cells. This creates a 'perfusion defect' visible on the PET scan.
Rubidium-82 has no significant pharmacological effect at the doses used for diagnostic imaging. It does not alter heart rate, blood pressure, or cardiac contractility. Its only 'effect' is the emission of radiation used for detection. The onset of action (uptake into the heart) is almost immediate, occurring within the first pass of the blood through the coronary circulation. The duration of the 'effect' is limited by its physical half-life of 75 seconds.
| Parameter | Value |
Common questions about Rubidium Muriaticum
Rubidium-82 is primarily used as a diagnostic tracer in Positron Emission Tomography (PET) scans to evaluate heart health. Specifically, it helps doctors see how well blood is flowing to the heart muscle, a process known as myocardial perfusion imaging. By identifying areas with poor blood flow, healthcare providers can diagnose coronary artery disease or assess damage after a heart attack. It is particularly useful because it provides high-resolution images very quickly. Only a qualified healthcare provider can determine if this test is appropriate for your cardiac evaluation.
The most common side effects associated with a Rubidium PET scan include a brief feeling of warmth or flushing, slight dizziness, and minor discomfort at the injection site. Many patients also experience side effects from the 'stress' medication given during the test, such as a temporary headache or nausea. Because Rubidium has an extremely short half-life, these effects usually disappear within a few minutes. Serious side effects are very rare but can include allergic reactions. Always report any discomfort to the imaging staff immediately.
While there is no direct chemical interaction between Rubidium and alcohol, you should avoid alcohol for at least 24 hours before your scheduled PET scan. Alcohol can affect your heart rate and blood pressure, which may interfere with the accuracy of the stress test results. Additionally, alcohol can cause dehydration, which might make it harder for the staff to start your IV. After the procedure is finished and the tracer has decayed (about 30 minutes), there are no specific restrictions on alcohol. However, always follow the specific pre-test instructions provided by your imaging center.
Rubidium-82 is generally avoided during pregnancy because it involves exposure to ionizing radiation, which can potentially harm a developing fetus. If you are pregnant or think you might be, it is crucial to inform your doctor before the scan. A risk-benefit analysis will be performed to see if the diagnostic information is vital for your immediate health. In most cases, alternative tests that do not use radiation, like an ultrasound, are preferred. If the scan must be done, the lowest possible dose will be used to minimize fetal exposure.
Rubidium works almost instantly once it is injected into your vein. It travels through your bloodstream and is taken up by your heart muscle within seconds. The PET scanner begins capturing images immediately after the infusion. Because the isotope decays so rapidly (half-life of 75 seconds), the entire imaging process for a 'rest' or 'stress' phase is usually completed in less than 10 to 15 minutes. This makes it one of the fastest diagnostic imaging procedures available in cardiology.
Rubidium is not a medication that you take on a regular basis; it is a one-time diagnostic tool administered by a doctor. Therefore, there is no 'stopping' the medication or risk of withdrawal. Once the injection is given, the radioactivity naturally disappears from your body within minutes due to its very short half-life. You do not need to take any special steps to 'clear' the drug from your system other than staying hydrated. Always follow your doctor's instructions for any other heart medications you may be taking.
Since Rubidium is administered by healthcare professionals in a hospital or clinic setting, you cannot miss a dose in the traditional way. If you miss your appointment for the PET scan, you simply need to reschedule it. If the infusion is interrupted for some reason during the procedure, the medical team will wait for the initial dose to decay and then decide if a second injection is necessary. It is important to arrive on time for your appointment because the Rubidium generator must be prepared specifically for your scheduled slot.
No, Rubidium does not cause weight gain. It is a diagnostic tracer used in a single, very small dose for imaging purposes. It does not have the metabolic or hormonal effects that lead to changes in body weight. Any weight changes you experience would be unrelated to the Rubidium PET scan. If you have concerns about weight changes related to other heart medications, such as beta-blockers or diuretics, you should discuss those with your cardiologist.
Rubidium can be used while you are on other medications, but some drugs must be temporarily stopped before the scan. For example, caffeine and certain heart medications like beta-blockers or nitrates can interfere with the accuracy of the PET scan images. Your doctor will provide you with a specific list of which medications to hold and for how long. It is vital to provide a complete list of all prescriptions, over-the-counter drugs, and herbal supplements to your imaging team. Never stop taking a prescribed medication without first consulting your doctor.
Rubidium-82 is not available as a 'generic' in the way that tablets like ibuprofen are. It is produced by a specialized medical device called a Rubidium-82 generator. There are different brands of these generators, such as CardioGen-82 and Ruby-Fill, which are approved by the FDA. While the Rubidium-82 chloride injection itself is the same, the delivery systems are proprietary. The cost and availability are usually handled by the hospital's nuclear medicine department rather than a retail pharmacy.
Other drugs with the same active ingredient (Rubidium)
> Warning: Stop the procedure and call your doctor immediately if you experience any of these during or after your Rubidium PET scan.
The primary long-term concern with Rubidium use is Radiation Exposure. Every exposure to ionizing radiation carries a theoretical risk of causing cancer many years later. However, the dose of radiation from a Rubidium-82 PET scan is relatively low—often lower than the radiation received from a traditional SPECT (Single Photon Emission Computed Tomography) heart scan. Healthcare providers use the 'ALARA' principle (As Low As Reasonably Achievable) to minimize these risks.
Radiation Risk and Infusion Volume Warning:
The FDA has issued warnings regarding the Rubidium-82 generator (specifically CardioGen-82) concerning the risk of 'Strontium breakthrough.' If the generator is not maintained correctly, Strontium-82 or Strontium-85 (which have much longer half-lives) could be accidentally injected into the patient. This would result in a significantly higher and potentially dangerous radiation dose to the bone marrow. Healthcare facilities are required to perform daily 'breakthrough' tests to ensure the purity of the Rubidium infusion.
Report any unusual symptoms to your healthcare provider. Even mild symptoms should be discussed with the imaging staff during your procedure.
Rubidium itself does not cause impairment. However, if a patient receives a sedative or a stress agent that causes dizziness, they should wait until these effects wear off before driving. Most patients can drive themselves home after a Rubidium PET scan once they have rested for a short period.
There are no known direct interactions between Rubidium and alcohol. However, alcohol should be avoided for at least 24 hours before a heart scan as it can affect heart rate and blood pressure, potentially complicating the interpretation of the results.
There is no 'tapering' required for Rubidium as it is a single-use diagnostic agent. There is no risk of withdrawal syndrome.
> Important: Discuss all your medical conditions, including any recent illnesses or radiation treatments, with your healthcare provider before starting Rubidium.
Rubidium does not typically interfere with standard blood chemistry or hematology tests. However, because it is a potassium analog, it could theoretically interfere with specialized assays for potassium if blood is drawn immediately after the infusion. This is rarely a clinical concern due to the 75-second half-life.
For each major interaction, the mechanism is usually pharmacodynamic (affecting the heart's response) rather than pharmacokinetic (affecting the drug's levels). The clinical consequence is reduced diagnostic accuracy. The management strategy is temporary discontinuation of the interfering substance under medical supervision.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for heart rhythm, blood pressure, or chest pain.
Conditions requiring careful risk-benefit analysis include:
There is little data on cross-sensitivity between Rubidium and other alkali metals (like Lithium or Cesium). However, patients with multiple chemical sensitivities or a history of reacting to various diagnostic dyes (though Rubidium is not a dye) should be monitored closely.
> Important: Your healthcare provider will evaluate your complete medical history, including your respiratory status and pregnancy status, before prescribing a Rubidium-based diagnostic procedure.
Clinical studies of Rubidium-82 did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
No dose adjustment is required for patients with renal impairment. However, since the kidneys are the eventual route of excretion for the stable decay products, patients with severe renal failure should be monitored for any unusual reactions. Dialysis does not significantly affect the clearance of the radioactive tracer because the decay is so rapid.
No dose adjustment is necessary for patients with hepatic impairment. Rubidium is not metabolized by the liver, and liver function does not affect the quality of the myocardial perfusion images.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding before any radiopharmaceutical procedure.
| Bioavailability | 100% (Intravenous) |
| Protein Binding | Negligible |
| Half-life (Physical) | 75 seconds |
| Tmax | < 2 minutes |
| Metabolism | Physical decay to Krypton-82 |
| Excretion | Renal (as stable isotopes) |
Rubidium is classified as a Radiopharmaceutical Diagnostic Agent. Within the EPC (Established Pharmacologic Class) system provided, it is associated with Calcium [EPC] and various allergenic extract classes, though its primary clinical grouping is with other PET tracers like Fluorodeoxyglucose (FDG) and Nitrogen-13 Ammonia.